

Medication review in Parkinson

Gepubliceerd: 17-03-2014 Laatste bijgewerkt: 15-05-2024

The expectation is that a structured medication review in primary care improves medication adherence and leads to positive patient outcomes in patients with Parkinson's Disease

Ethische beoordeling	Positief advies
Status	Werving nog niet gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON21486

Bron

Nationaal Trial Register

Verkorte titel

Medication review in Parkinson

Aandoening

Parkinson's Disease
Therapy adherence
Medication
Polypharmacy

Ondersteuning

Primaire sponsor: Medisch Spectrum Twente

Overige ondersteuning: Medisch Spectrum Twente

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

The primary objective of the study is to assess whether a structured medication review improves medication adherence and leads to better quality of life in patients with PD after a

follow-up of three months and six months, compared to patients with PD who will not receive a structured medication review during follow-up. Disease-specific quality of life will be measured, using the Parkinson's Disease Questionnaire-39 (PDQ-39).

Toelichting onderzoek

Achtergrond van het onderzoek

The aim of this study is to assess whether a structured medication review in primary care improves medication adherence and leads to positive patient outcomes in patients with PD. The expectation is that the results of this study might be used to improve daily treatment of patients with PD.

Doel van het onderzoek

The expectation is that a structured medication review in primary care improves medication adherence and leads to positive patient outcomes in patients with Parkinson's Disease

Onderzoeksopzet

- Baseline
- Three months
- Six months

Onderzoeksproduct en/of interventie

The study is a prospective randomized, controlled trial (RCT).

As intervention, community pharmacists perform a structured medication review as one-time assessment at the start of the study within the intervention group. Measurements at baseline will be done before the intervention. The follow-up measurements will take place after three months and six months.

A structured medication review can be defined as 'a structured, critical examination of a patient's medicines with the objective of reaching an agreement with the patient about treatment, optimizing the impact of medicines, minimizing the number of medication-related problems and reducing waste'

Contactpersonen

Publiek

Medisch Spectrum Twente,
P.O. Box 50000

J. Palen, van der
Enschede 7500 KA
The Netherlands
+31 (0)53 4872023

Wetenschappelijk

Medisch Spectrum Twente,
P.O. Box 50000

J. Palen, van der
Enschede 7500 KA
The Netherlands
+31 (0)53 4872023

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

The patient has/is:

- Diagnosed with PD according to the UK-brain banking criteria
- $\geq$ Eighteen years of age
- $\geq$ Four different medications daily
- $\geq$ Four medication intake moments daily
- Expressing motor symptoms or non-motor symptoms
- Living (semi)-independent in the region of Enschede
- Able to read and write the Dutch language

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

The patient has/is:

- Unable to administrate own medications, excluding PD patients with personal or family home caregivers
- Received a medication review within a year before the study

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Toewijzing:	Gerandomiseerd
Blinding:	Open / niet geblindeerd
Controle:	Geneesmiddel

Deelname

Nederland	
Status:	Werving nog niet gestart
(Verwachte) startdatum:	01-05-2014
Aantal proefpersonen:	198
Type:	Verwachte startdatum

Ethische beoordeling

Positief advies	
Datum:	17-03-2014
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 44681

Bron: ToetsingOnline

Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL4360
NTR-old	NTR4500
CCMO	NL48661.044.14
OMON	NL-OMON44681

Resultaten